SOUTH SAN FRANCISCO--(BUSINESS WIRE)--TRex Bio, Inc. (“TRexBio”), a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, today announced the close of an oversubscribed $84 million Series B financing round. The financing was led by Delos Capital (“Delos”), with additional new investors Avego BioScience Capital (“Avego”) and Agent Capital.

南旧金山——（商业新闻短讯）——TRex Bio，Inc.（“TRexBio”）是一家解码人体组织免疫生物学以创造革命性治疗方法的生物技术公司，今天宣布结束一轮超额认购的8400万美元B系列融资。融资由Delos Capital（“Delos”）牵头，另外还有新投资者Avego BioScience Capital（“Avego”）和代理资本。

Existing investors Eli Lilly and Company (“Lilly”), SV Health Investors, Pfizer Ventures, Johnson & Johnson (through its venture capital arm, Johnson & Johnson Innovation – JJDC, Inc.), Alexandria Venture Investments, and Polaris Partners also participated..

现有投资者Eli Lilly and Company（“Lilly”）、SV Health investors、辉瑞风险投资公司、强生公司（通过其风险投资部门，强生创新-JJDC，Inc.）、亚历山大风险投资公司和Polaris Partners也参加了会议。

Proceeds from the financing will be used to advance TRexBio’s lead candidate, TRB-061, a purpose-engineered TNFR2 agonist, through early clinical proof of concept in patients with immune mediated diseases including atopic dermatitis and ulcerative colitis. TNFR2 is a receptor that is highly expressed on the most suppressive regulatory T cells (“Tregs”) in skin and gut.

通过免疫介导疾病（包括特应性皮炎和溃疡性结肠炎）患者的早期临床概念验证，融资收益将用于推进TRexBio的主要候选药物TRB-061（一种专门设计的TNFR2激动剂）。TNFR2是一种在皮肤和肠道中最具抑制性的调节性T细胞（“Tregs”）上高度表达的受体。

TRB-061 is designed to selectively agonize TNFR2, activating tissue-licensed Tregs to address a range of inflammatory and autoimmune conditions. TRexBio expects to initiate a Phase 1 clinical trial with TRB-061 in the first half of 2025. The funding will also support the expansion of TRexBio’s pipeline, including early development of therapeutic candidate TRB-071.

TRB-061被设计用于选择性地激动TNFR2，激活组织许可的Tregs以解决一系列炎症和自身免疫病症。TRexBio预计在2025年上半年启动TRB-061的1期临床试验。该资金还将支持TRexBio管道的扩展，包括早期开发治疗候选TRB-071。

TRB-061 will be the second program to enter the clinic out of TRexBio’s proprietary platform, following TRB-051 currently in Phase 1 under a collaboration with Lilly. TRexBio also has an ongoing collaboration with Johnson & Johnson for a preclinical program from its platform-based collaboration..

TRB-061将是继TRB-051目前在与礼来合作的第一阶段之后，第二个从TRexBio专有平台进入诊所的项目。TRexBio还通过其基于平台的合作与强生公司进行了临床前项目的持续合作。

“We are grateful for the support and partnership of our investors, who share our vision for a differentiated approach to the treatment of autoimmune and inflammatory disease, one built on immune homeostasis rather than simply on suppression,” said Johnston Erwin, CEO of TRexBio. “The funding from this Series B financing enables us to enter the clinic early next year with TRB-061, and to start exploring the breadth of potential therapeutic applications for this novel therapy.

TRexBio首席执行官约翰斯顿·欧文（JohnstonErwin）表示：“我们感谢投资者的支持和合作伙伴关系，他们与我们一样，对治疗自身免疫性和炎症性疾病的差异化方法有着共同的愿景，这种方法建立在免疫稳态的基础上，而不仅仅是抑制。”这项B系列融资的资金使我们能够在明年年初与TRB-061一起进入诊所，并开始探索这种新型疗法的潜在治疗应用范围。

We continue to believe that our unique, tissue-focused approach will enable first- and best-in-class programs with potential to address significant unmet patient need.”.

我们仍然相信，我们独特的，以组织为中心的方法将使一流的和最好的课程有可能解决严重未满足的患者需求。”

In connection with the financing, TRexBio announced that Eric Huang, PhD, Partner at Delos; Joel S. Marcus, Executive Chairman & Founder at Alexandria Venture Investments; and Eric Pham, PhD, Managing Director at Avego have joined the company’s Board of Directors.

关于融资，TRexBio宣布，Eric Huang博士是Delos的合伙人；亚历山大风险投资公司（Alexandria Venture Investments）执行主席兼创始人乔尔·马库斯（JoelS.Marcus）；Avego董事总经理Eric Pham博士也加入了公司董事会。

“Regulatory T cells—and TRexBio’s lead program TRB-061 in particular—offer the potential to unlock a new pillar of therapeutic care for autoimmune and inflammatory diseases,” said Dr. Eric Huang. “Our goal at Delos is to invest in companies with strong scientific foundations and clear visions for changing clinical standards of care.

Eric Huang博士说：“调节性T细胞和TRexBio的主要项目TRB-061特别有可能为自身免疫性和炎性疾病的治疗开辟新的支柱。”。“我们在Delos的目标是投资于具有强大科学基础和清晰愿景的公司，以改变临床护理标准。

We have been impressed by TRexBio's rigorous scientific approach and innovative platform for harnessing the natural function of regulatory T cells to establish immune balance. We’re proud to support TRexBio's work, which we believe will soon translate into safe, durable, and effective medicines that improve the lives of many patients.”.

TRexBio严格的科学方法和创新平台给我们留下了深刻的印象，这些方法和平台可以利用调节性T细胞的自然功能来建立免疫平衡。我们很自豪地支持TRexBio的工作，我们相信这将很快转化为安全，耐用和有效的药物，改善许多患者的生活。”

About TRexBio

关于TRexBio

TRexBio is a biotechnology company developing purpose-built therapeutics by leveraging cutting edge computational biology tools, a focus on human tissue, and expertise in immunobiology. Our Deep Biology platform maps human tissue Treg behavior to disease processes to identify and characterize novel targets for therapeutic intervention.

TRexBio是一家生物技术公司，通过利用尖端的计算生物学工具，专注于人体组织和免疫生物学专业知识，开发专门的治疗方法。。

Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis. TRexBio was founded and seed funded by SV Health Investors in 2018 and is headquartered in South San Francisco, California. TRexBio was one of the first companies in residence at Lilly Gateway Labs, a shared innovation space where Eli Lilly and Company enables and engages high-caliber, early-stage biotechs to do break-through science.

利用这个平台，我们正在建立广泛的新型疗法组合，调节免疫系统以恢复人体组织免疫稳态。TRexBio于2018年由SV Health Investors成立并获得种子资金，总部位于加利福尼亚州南旧金山。TRexBio是礼来Gateway Labs首批入驻的公司之一，礼来Gateway Labs是礼来公司与公司共享的创新空间，使高质量的早期生物技术能够突破科学。

For more info, visit www.trex.bio..

For more info, visit www.trex.bio..

About Delos

关于德洛斯

Delos Capital is a life sciences investment firm, founded in 2014, that empowers extraordinary teams to turn bold ideas into medical breakthroughs. We are a partnership comprised of seasoned entrepreneurs and scientists, committed to investing our time and capital into a positive and lasting impact on human health.

Delos Capital是一家成立于2014年的生命科学投资公司，它授权非凡的团队将大胆的想法转化为医学突破。我们是一个由经验丰富的企业家和科学家组成的伙伴关系，致力于将我们的时间和资本投入到对人类健康的积极和持久影响中。

We derive our conviction from a rigorous investment process that focuses on connecting cutting-edge science with well-defined clinical need. For more information, please visit www.deloscapital.com..

我们的信念来自严格的投资过程，该过程侧重于将尖端科学与明确的临床需求联系起来。欲了解更多信息，请访问www.deloscapital.com。